Edition:
United Kingdom

People: Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

59.01USD
21 Aug 2019
Change (% chg)

-- (--)
Prev Close
$59.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
67,515
52-wk High
$82.33
52-wk Low
$36.10

Pernock, David 

Mr. David M. Pernock is President, Chief Operating Officer of the Company. Previously, Mr. Pernock served as a member of our Board from April 2015 until January 2017. Before becoming our President and Chief Commercial Officer in January 2017, Mr. Pernock served as chairman of the board of directors since September 2009 and as chief executive officer since February 2010 of Fibrocell Science, Inc., a publicly-traded autologous cell and gene therapy company. From December 1993 until November 2009, Mr. Pernock held various positions at GlaxoSmithKline, eventually serving as senior vice president of pharmaceuticals, vaccines (biologics), oncology, acute care, and HIV divisions. From May 2009 until February 2011, Mr. Pernock served as a director of Martek Biosciences Corporation. Mr. Pernock holds a B.S. in business administration from Arizona State University.

Basic Compensation

Total Annual Compensation, USD 540,653
Restricted Stock Award, USD 1,493,300
Long-Term Incentive Plans, USD --
All Other, USD 1,641,490
Fiscal Year Total, USD 3,675,440

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Graves

392,278

David Pernock

3,675,440

Scott Tarriff

11,324,500

Pete Meyers

2,673,850

Adrian Hepner

3,134,840

Douglas Braunstein

319,778
As Of  31 Dec 2018